The effect of statins on prostate cancer recurrence and mortality after definitive therapy: a systematic review and meta-analysis.

In this work, we aim to further analyze the association of statins use with biochemical recurrence (BCR) of prostate cancer (PCa) and PCa-specific mortality after definitive therapy. A systematic literature search of PubMed, MEDLINE, and EMBASE through Jul 2015 was conducted. Pooled Hazard ratio (HR) estimates with corresponding 95% confidence intervals (CIs) were calculated using random-effects model. STATA version 10 (Stata corporation, college station, TX) was employed to conduct all statistical analyses. A total of 22 and 8 studies contributed to the biochemical recurrence analysis and PCa-specific mortality, respectively. 13 trials were included for BCR-free survival analysis. The combined result showed statins users had lowered 12% BCR risk of PCa compared with non-users (HR = 0.88, 95%CI: 0.765-0.998) (p < 0.05). The association was null among the men who underwent radical prostatectomy as primary therapy (HR = 0.96, 95%CI: 0.83-1.09), while the improved outcomes had be seen among patients who received radiation therapy (HR = 0.67, 95%CI: 0.48-0.86). After excluding the patients undergoing ADT, participants did not benefit from statins use (HR = 0.94, 95%CI: 0.77-1.11). Meanwhile, long-term statins using did not alter recurrence risk. A lower risk of prostate cancer-specific mortality was observed among statins users (HR = 0.68, 95%CI: 0.56-0.80). There was a plausible trend towards increasing the BCR-free survival rate among statins users.

Prostate cancer (PCa) is the most commonly diagnosed malignancy among men in the US. Approximately 220,800 American males are estimated to have been diagnosed with prostate cancer in 2015, and 27,540 will die of the disease1. Unfortunately, up to 40% of patients experienced postoperative disease recurrence or progression on long-term follow-up2. Statins are wildly used medications for lowering hypercholesterolemia. Interestingly, some reports declaims that statins have been associated with a reduced incidence of PCa, with evidence being particularly strong for advanced PCa34. This effect may be related to both cholesterol and non-cholesterol-mediated mechanisms. While, the impact of statins use on the incidence and natural history of PCa remains controversial56. Moreover, there is increasingly considerable interest in the potential ability of statins to improve PCa outcomes and decrease recurrence risk after definitive therapy.

A recent meta-analysis, including a total of 13 studies, provided the evidence that statins use could not reduce the recurrence risk among men treated with definitive therapy7. While, these studies included in Park et al.7 covered heterogeneous and limited sized cohorts. Moreover, nine more studies were published after that7 and provided further evidence on this topic. Thus, a further analysis of the association of statins use with recurrence risk after definitive therapy for PCa is warrant. Furthermore, whether statins have effect on the PCa-specific mortality still remained unknown.

Methods

Study selection

We performed a literature search without language restrictions using the databases of PubMed (Jan 1967–April 2015), MEDLINE (Jan 1967–April 2015), EMBASE (Jan 1990–April 2015) to include all studies that investigate the association of statins use with prostate cancer outcomes. In addition, a manual search was conducted to identify additional relevant studies. After removing duplicate publications, two reviewers (Tan & Wei) independently assessed all remaining results by checking titles and abstracts. All publications, including abstracts, were eligible for retrieval. When studies reported outcomes from similar or overlapping databases or cohorts, only data from the most recent publication were included. The studies included should analyze the BCR, PCa-specific mortality, or BCR-free survival. BCR defined as a post-treatment PSA value of 0.2 ng/ml or greater in men who underwent radical prostatectomy; nadir PSA level +2 ng/ml (Phoenix criteria), for men treated with radiation therapy; or any PSA increase in men treated with primary androgen deprivation therapy; and not any evidence of clinical and/or radiographically detected disease. We adapted a PRISMA (preferred reporting items for systematic reviews and meta-analyses) flow-chart to depict the study selection.

Data extraction and analysis

Data from each study were independently extracted by two reviewers (Tan & Wei) using a standardized data-extraction form. Any disagreements were resolved by consensus or by consultation with a third reviewer (Yang). Adjusted multivariate Hazard ratio (HR) with corresponding 95% confidence intervals (CIs) were used to assess potential association between statins use and BCR and mortality of prostate cancer following treatment. In addition, we also tried to contact authors via e-mail to obtain further information that had not been reported in their published articles. We identified heterogeneity between studies using the standard Cochran’s Q test with a significance level of α = 0.10. We also examined heterogeneity with the I statistic, which quantifies inconsistency across studies to assess the impact of meta-analysis heterogeneity. An I statistic of 50% or more indicates a considerable level of heterogeneity. When heterogeneity was found, we attempted to determine potential sources of heterogeneity through stratification by various factors, and inference analysis and exclusion sensitivity analyses. Publication bias was detected using both the Begg’s and Egger’s tests. Statistical significance was determined using the two-tailed test, where P < 0.05 was considered significant. STATA version 10 (Stata corporation, college station, TX) was employed to conduct all statistical analyses.

Results

A total of 3229 publications were identified during the initial search (see Additional file 1.), and after employing exclusion criteria, a total of 22 studies were included for PCa recurrence analysis891011121314151617181920212223242526272829 (Table 1), 8 trials were available for PCa-specific mortality2230313233343536 (Table 2), and 13 for BCR-free survival analysis891114172025293637383940 (Table 3). Among 22 studies included in meta-analysis for PCa recurrence, 14 included a population primarily treated with radical prostatectomy (RP). Meanwhile, men in seven studies were treated with radiation therapy (RT-either external beam, brachytherapy or a combination of them). And other one study in which included patients were treated with RP, RT with or without ADT (androgen deprivation therapy) or ADT only22. Among 8 trials included for PCa specific mortality, one included a population of diabetic men34. Two abstract were included in BCR-free survival analysis.

Table 1

Study characteristics of 22 included studies of the association between statins use and biochemical recurrence risk of PCa after definitive therapy.

Study (year)	Country	Primary treatment(s)	No. of patients	No. of patients on statins	No. of recurrence patients	ADT (%)	Estimate(s)(95% confidence interval, CI)
Moyad et al. (2006)8	US	brachytherapy+EBRT	938	191	39	40.7	HR:1.5 (0.33–6.94)
Soto et al. (2009)9	US	3D-RT or IMRT	968	220	NR	28.9	HR:1.1 (0.8–1.6)
Rioja et al. (2010)10	US	RP	3748	2664	249	0.0	HR:1.15 (0.89–1.50)
Gutt et al. (2010)11	US	brachytherapy+EBRT	691	189	113	41.0	HR:0.43(0.25–0.73)
Hamilton et al. (2010)12	US	RP	1319	236	304	18.0	HR:0.70 (0.50–0.97)
Krane et al. (2010)13	US	rRP	3828	1031	NR	1.5	HR:0.99 (0.83–1.18)
Kollmeier et al. (2011)14	US	3D-RT or IMRT	1681	382	301	56.0	HR:0.69 (0.50–0.97)
Ku et al. (2011)15	Korean	RRP	687	87	145	0.0	HR:1.18 (0.67–2.10)
Mondul et al. (2011)16	US	RRP	2399	779	127	0.0	HR:0.99 (0.64–1.55)
Ritch et al. (2011)17	US	RP	1261	281	NR	0.0	HR:1.54 (1.00–2.20)
Zaorsky et al. (2012)18	US	3D-CRT+IMRT	2051	691	177	0.0	HR:0.63 (0.49–0.82)
Mass et al. (2012)19	US	ORRP	1446	437	166	NR	HR:1.15 (0.82–1.61)
Rieken et al. (2013)20	Multicenter	RP	6842	2275	778	0.0	HR:0.88 (0.76–1.03)
Kontraros et al. (2013)21	Greece	RP	588	107	187	0.0	HR:1.63 (1.19–2.24)
Geybels et al. (2013)22	US	RP, RT	1001	289	151	NR	HR:1.06 (0.74–1.54)
Chao et al. (2013)24	US	EBRT	774	401	145	67.0	HR:0.99 (0.70–1.39)
Chao et al. (2013)24	US	RP	1184	446	156	0.0	HR:1.00 (0.72–1.39)
Oh et al. (2014)25	US	Brachytherapy+EBRT	247	174	18	25.9	HR:0.29 (0.09–0.89)
ishak-Howard et al. (2014)26	US	RRP	539	258	115	NR	HR:1.06 (0.68–1.64)
Allott et al. (2014)27	US	RP	1146	400	402	0.0	HR:0.64 (0.47–0.87)
Danzig et al. (2015)29	US	RP	669	76	147	0.0	HR:1.20 (1.50–2.60)
Song et al. (2015)28	Korea	rRP or ORRP	1896	211	466	0.0	HR:0.64 (0.40–1.05)

Note: XRT, external beam radiotherapy (XRT); RRP, radical retropubic prostatectomy; 3D-CRT, 3-dimensional conformal radiation therapy; IMRT, intensity modulated radiation therapy; ORRP, open radical retropubic prostatectomy; rRP, robotic radical prostatectomy.

Table 2

Study characteristics of 8 studies of the association between statins use and prostate cancer-specific mortality.

Study (year)	Country	Duration of follow-up (Mean ± SD)	All male subjects (%)	No. of died from PCa*	Estimate(s)(95% confidence interval, CI)
Serruys et al. (2002)30	Multicenter	3.9y	1406 (83.8)	4	HR:0.98 (0.14–6.92)
Marcella et al. (2011)31	US	NR	760 (100.0)	380	HR:0.45 (0.29–0.71)
Nielsen et al. (2012)32	Denmark	2.6y	27752 (100.0)	10542	HR:0.81 (0.75–0.88)
Grytli et al. (2013)33	Norway	39 M	3699 (100.0)	NR	HR:0.78 (0.67–0.90)
Geybels et al. (2013)22	US	6.1y	1001 (100.0)	39	HR:0.19 (0.06–0.56)
Margel et al. (2013)34	Canada	4.64y	3837 (100.0)	291	HR:0.78 (0.62–0.99)
Yu et al. (2014)35	UK	4.4y ± 2.9	11772 (100.0)	1791	HR:0.76 (0.66–0.88)
Caon et al. (2014)36	Canada	8.4y	3851 (100.0)	NR	HR:0.77 (0.55–1.08)

*PCa, prostate cancer.

Table 3

Characteristics of 13 studies evaluating the effect of statins on Biochemical Recurrence-Free Survival.

Sources (year)	Primary treatment(s)	No. of patients	Biochemical Recurrence-Free Survival Rate
			Duration: Statins users (%) vs Non-statin users (%); P-value
Katz et al. (2003)37	RT#	905	5 year: 88.8% vs 71.2%; P = .009
Moyad et al. (2006)8	RT	938	9 year: 98.4% vs 95.2%; P = 0.062
Shippy et al. (2007)38	RT	871	10-year: 76% vs 66%; P = 0.01
Soto et al. (2009)9	RT	968	5 year: 67% vs 57%; P = 0.03
Gutt et al. (2010)11	RT	691	4 year: 93% vs 80%; P < 0.001
Kollmeier et al. (2011)14	RT	1711	5 year: 89% (95%CI, 85–92%) vs 80% (95%CI, 72–86%) 8 year: 83% (95%CI, 81–85%) vs 74% (95%CI, 71–77%)
Ritch et al. (2011)17	RP$	1261	5 year: 75% vs 84%; P < 0.05
Misrai et al. (2012)39	RP	377	2 year: 93% vs 88%; P = 0.16
Rieken et al. (2013)20	RP	6842	2 year: 94 ± 1% vs 92 ± 0%; P = NR* 5 year: 84 ± 1% vs 82 ± 1%; P = NR 10 year: 71 ± 3% vs 66 ± 3%; P = NR
Caon et al. (2014)36	RT ± ADT	3851	10-year: 94.1% vs 91.2%; P = 0.031
Oh et al. (2014)25	RT	247	5 year: 97.2% vs 89.6%; P = 0.007
Cuaron et al. (2015)40	RT	754	8-year: 84.5% vs 88.2%; P = 0.85
Danzig et al. (2015)29	RP	767	2-year: 79.0% vs 79.3%; P = NR 5-year: 63.7% vs 72.4%; P = NR

*NR, not report.

#RT, radiation therapy.

$RP, radical prostatectomy.

Statins and biochemical recurrence risk of PCa

Most studies demonstrated that statins had a neutral effect on recurrence after prostate cancer diagnosis. Overall, the combined result showed statins users had lowered the risk of recurrence compared with non-users (HR = 0.88, 95%CI: 0.765–0.998, I = 65.6%, p < 0.001) (Fig. 1). The association was null among the men who underwent RP as primary therapy (HR = 0.96, 95%CI: 0.83–1.09, I = 57.5%, p = 0.004). However, the combined result showed an inverse association between statins use and recurrence after treatment of RT (HR = 0.67, 95%CI: 0.48–0.86, I = 60.9%, p < 0.001). It is really important to exclude patients undergoing ADT, in order to reduce the correlation between metabolic syndrome secondary androgen deprivation and BCR, as reported in literature. After excluding patients undergoing ADT, 11 studies were included and the combined estimates suggested that no patient had benefit from statins use after local therapy (HR = 0.94, 95%CI: 0.77–1.11) (Fig. 2). Additional file 2 and file 3 shown, long-term statins use still cannot alter recurrence risk (HR = 0.90, 95%CI: 0.72–1.07). No publication bias was detected among 22 studies when Begg’s and Egger’s tests were conducted (p = 0.81, p = 0.87, respectively) (see Additional file 4).

Figure 1

The effect of statins on BCR risk of prostate cancer among men following definitive therapy.

Figure 2

The effect of statins on BCR risk of prostate cancer among men who did not receive ADT pre- or post-local therapy.

In the stratified analysis, the pooled HR estimates suggested that reverse relationship between statins use and PCa recurrence was observed in the US (HR = 0.86, 95%CI: 0.73–0.99). However, we failed to find a similar relation in the non-US (HR = 1.01, 95%CI: 0.67–1.35). When stratified analyses were performed on the results with or without adjusted for age, BMI, or PSA, we observed that statins use had a neutral effect on PCa recurrence when adjusted for them. Post-operation and pre-operation statins use both cannot alter PCa recurrence risk. Detailed data are illustrated in Table 4.

Table 4

Pooled estimates of BCR analyses in subgroups.

Sources	No. of studies	Pooled estimates		Tests of heterogeneity		Tests of publication bias
		HR	95%CI	I2(%)	p-val.	Begg’s p-val.	Egger’s p-val.
All studies	22	0.88	0.765–0.998	66.8	<0.001	0.809	0.866
Treatment modality
RP	14	0.96	0.83–1.09	57.5	0.004	0.784	0.518
RT	7	0.67	0.48–0.86	60.9	0.018	0.881	0.753
Exclude pts received ADT	11	0.94	0.77–1.11	68.5	<0.001	0.533	0.493
RP	10	0.99	0.81–1.17	62.9	0.004	0.788	0.500
RT	1	0.63	0.63–0.79	–	–	–	–
Include pts received ADT	8	0.74	0.54–0.95	71.5	0.001	0.712	0.453
RT	6	0.69	0.43–0.96	67.5	0.009	0.851	0.495
RP	2	0.86	0.57–1.14	73.4	0.052	–	–
Pre- or post-operation	7	0.87	0.69–1.04	51.9	0.052	1.000	0.760
Post-operation	5	0.83	0.61–1.05	59.0	0.045	0.806	0.740
Pre-operation	2	1.00	0.75–1.24	0.0	0.967	–	–
Results for long-term statins use	7	0.90	0.72–1.07	11.8	0.340	0.548	0.529
Park et al. analysis
Before	12	0.89	0.72–1.06	70.5	<0.001	0.945	0.994
After	10	0.88	0.70–1.05	65.0	0.002	0.929	0.865
Country
US	18	0.86	0.73–0.99	66.6	<0.001	0.879	0.710
Non-US	4	1.01	0.67–1.35	71.6	0.014	0.497	0.730
PSA
Adjusted	11	0.95	0.81–1.09	52.5	0.021	0.697	0.401
Not adjusted	11	0.80	0.60–0.99	73.3	<0.001	0.697	0.592
BMI
Adjusted	6	0.93	0.71–1.16	71.9	0.003	0.851	0.943
Not adjusted	16	0.86	0.72–1.01	66.5	<0.001	0.928	0.948
Age
Adjusted	8	0.96	0.81–1.12	59.0	0.017	0.621	0.495
Not adjusted	14	0.82	0.65–0.98	65.5	<0.001	0.913	0.873
BMI & Age
Adjusted	4	1.00	0.68–1.32	80.1	0.002	0.497	0.954
Not adjusted	18	0.86	0.73–0.98	63.5	<0.001	1.000	0.967
BMI or PSA or Age
Adjusted	12	0.95	0.83–1.07	50.3	0.023	0.681	0.490
Not adjusted	10	0.76	0.55–0.97	68.2	0.001	0.929	0.865

Note: HR, Hazard ratio; 95%CI, 95% confidence intervals; PCa, prostate cancer; PSA, prostate-specific antigen; RT, radiation therapy; RP, radical prostatectomy. BCR, biochemical recurrence.

While there was limited data of the effect of statins on local recurrence and metastasis of PCa after treatment. For low-, intermediate- and high-risk group, statins use did not affect the recurrence risk14. The Mondual et al. also observed that statins using was not associated with the progression to metastasis or death of PCa after treatment16.

Statins and prostate cancer specific mortality

Eight studies evaluated exposure to statins and the recurrence of PCa. Figure 3 graphed the HRs and 95%CIs from individual studies and the pooled results. Among them, six studies showed an inverse association. The combined estimates of eight studies showed a decreased risk (HR = 0.68, 95%CI: 0.56–0.80) (Table 5). After excluding Serruys et al.30, due to its large confidence interval (HR = 0.98, 95%CI: 0.14–6.92), the result of seven studies was consistent and stable (HR = 0.68, 95%CI: 0.55–0.80). There was no publication bias (Begg’s test, p = 0.386; Egger’s test, p = 0.063). After adjusting for age, BMI, or PSA, the same trends were observed in these subgroups (see Table 5).

Figure 3

The relationship between statins use and prostate cancer-specific mortality.

Table 5

Pooled estimates of Mortality analyses in subgroups.

Sources	No. of studies	Pooled estimates		Tests of heterogeneity		Tests of publication bias
		HR	95%CI	I2(%)	p-val.	Begg’s p-val.	Egger’s p-val.
PCa-specific mortality	8	0.68	0.56–0.80	77.2	<0.001	0.386	0.063
Exclude Serruys et al.	7	0.68	0.55–0.80	80.5	<0.001	0.072	0.018
Age
Adjusted	5	0.64	0.48–0.79	87.0	<0.001	0.086	0.004
Not adjusted	2	0.78	0.60–0.97	0.0	0.908	–	–
BMI
Adjusted	2	0.62	0.32–0.92	84.8	0.010	–	–
Not adjusted	5	0.68	0.50–0.85	82.0	<0.001	0.806	0.258
PSA
Adjusted	3	0.61	0.35–0.86	89.4	<0.001	1.000	0.077
Not adjusted	4	0.70	0.51–0.89	70.9	0.016	0.734	0.445
BMI & Age
Adjusted	2	0.62	0.32–0.92	84.8	0.010	–	–
Not adjusted	5	0.68	0.50–0.85	82.0	<0.001	0.806	0.258
BMI or PSA or Age
Adjusted	5	0.64	0.48–0.79	87.0	<0.001	0.086	0.004
Not adjusted	2	0.78	0.60–0.97	0.0	0.908	–	–

Note: HR, Hazard ratio; 95%CI, 95% confidence intervals; PCa, prostate cancer; PSA, prostate-specific antigen.

Effect of statins on BCR-free survival

Table 3 showed 13 retrospective studies were included to evaluate the effect of statins on biochemical recurrence-free survival. The 5-year BCR-free survival rate of statins users ranged from 63.7 to 97.2% and that was 57–89.6% for non-users. The statins users had much higher 10-year BCR-free survival rate compared with non-users.

Sensitivity analysis

Sensitivity analyses were conducted to evaluate the effect of each study on the overall estimates by sequentially excluding each study in turn. In our meta-analysis, we found that probably no study could affect the summary of risk estimates, means that the results remained stable (data not shown).

Discussion

In this meta-analysis among men following definitive treatment of localized prostate cancer, approximately 12% reduction risk of recurrence in statins users was found (p < 0.001). In cumulative meta-analysis, a reduction risk was found for the first time in 2010, when Hamilton et al.12 joined the analysis. When analyzed by treatment modality, statins use had a neutral effect on BCR risk among men who underwent radical prostatectomy. On the contrary, there was almost 33% lower risk of recurrence among statins users who received RT as primary treatment modality. These are consistent with the results from subgroup patients who did not receive adjuvant ADT. The benefits were null when estimates controlled for age, BMI or PSA. Overall, there was 32% lower risk of prostate cancer-specific mortality among statins users. To our knowledge, this is the first meta-analysis to address the relationship between PCa-specific mortality and statins use.

Whether the improved outcomes seen among patients who underwent RT reflecting that statins directly inhibit PCa progression, act as a radiosensitizer, or are the result of either residual confounding or type I error of studies is unknown. One postulated possible explanation was statin-induced radiosensitizing effects. Prostate cancer cell death was increased in both in vitro and in vivo models when combined the statins and ionizing radiation, which might attributed to the MYC oncogene, as statins decreasing cellular MYC levels1141. Statins also play a synergistic role with radiation by promoting autophagy pathway, causing prostate cancer cell death42. Moreover, Gutt et al.11 proved that a larger benefit was seen in men treated with lower radiation doses. Clinically, RT combined with ADT were often used to treat PCa. In our work, seven studies analyzed men who treated by RT, but six of them included patients who received ADT. As ADT could reduce PCa recurrence risk, the effect of statins could not be confirmed there.

Intriguingly, our findings do not support the hypothesis that statins, when taken at low dose for managing hypercholesterolemia, can reduce the risk of PCa recurrence among men treated with RP as primary therapy. Although many studies found the statins had antineoplastic properties, two precious high quality meta-analyses had confirmed that statins use could not reduce the risk of prostate cancer54344. Another plausible explanation is that statins are associated with a dose-dependent reduction in the risk of biochemical recurrence. The effect of statins on lowering recurrence risk was observed only when taken at doses ≥1 DE (dose equivalents)12. Many in vitro studies that demonstrated these protective effects also used statins concentrations that were much higher than those seen with standard therapeutic use.

This meta-analysis suggested that regular statins use reduced 32% risk of PCa-related mortality. Meanwhile, Marcella et al.31 evaluated effect of statin type on prostate cancer mortality, which showed that hydrophilic and lipophilic statins both lowered the risk of PCa-specific mortality. However, there was a trend based on potency in which high-potency statins were associated with a 73% risk reduction, whereas this effect was not observed in low-potency statins.

One of 13 trials evaluating the BCR-free survival suggested that statins users had a lower 5-year BCR-free survival rate compared with non-users17, while some reveled reversely92537 or showed there was no difference between two groups20. Meanwhile, the BCR-free survival rate at 8 or 9-year were still inconsistent81440. However, the BCR-free survival rate at 10 year among statins users was much higher compared with non-users3638. These inconsistencies might be attributed to the composition of risk group of patients, as lower-risk group had higher 5-year BCR-free survival rate compared with intermediate-risk and high-risk group9111417. Meanwhile, treatment modality and the radiation doses among men who underwent RT also contributed to this inconsistency12. Overall, there is a plausible trend towards increasing the BCR-free survival rate among statins users.

Given the known that income, education and health insurance coverage influence access to appropriate early detection, statins users are more likely to get PSA testing done and treatment, leading percent of low or intermediate-risk patients much higher among statins users than that in non-users. This might cause an illusion that statins have protective effect. The possible confounding effect arising due to the indications for which statins are prescribed also needs to be emphasized. Statins users are more likely to be obese or older as compared to non-users. This could affect PCa outcomes or progression. The subgroup analyses of 6 studies which adjusted for BMI or age reveled a neutral effect on BCR. This effect was also observed in the combined estimates of four studies adjusted for both BMI and age.

A previous meta-analysis, including 8 studies, initially addressed the relationship between statins use and PCa recurrence and showed that there was no association between statins use and recurrence after prostate cancer diagnosis (HR = 0.91, 95%CI: 0.72–1.13), this effect was consistent with men received RP or RT45. After that, another meta-analysis included 13 studies in the formal meta-analysis was conducted, which showed the same relationship (HR = 0.90, 95%CI: 0.74–1.08), while a reverse association was initially observed among men accepted RT (HR = 0.68, 95%CI: 0.49–0.93)7. Compared with Park et al.7, after including 9 more new studies that provided stronger evidence, we found a reverse association with statins among men following definitive treatment. Besides, Oh et al.25 updated their data in 2014, which may also contribute to this inconsistency. Unexpectedly, the combined result of these 10 studies showed a neutral effect of statins use on recurrence risk (HR = 0.88, 95%CI: 0.70–1.05).

Some limits in our meta-analysis should be mentioned. First, the available literature was limited to English language, which might be subject to selective bias and confounding. Second, there was significant heterogeneity among studies that might be attributed to various percent of risk groups. In a study, the beneficial effect was limited to high-risk patients, which proved that risk groups could affect the recurrence-free survival14. While, the data in different risk groups was limited; thus, the future studies addressing this topic should take the risk groups into account. Another potential factor contributed to this heterogeneity was starting time of statins use, which means some patients started using statins before operation (RT or RP or both), some started using during operation, while others received statins for the first time after operation. Third, the overall result showed that statins use lowered the recurrence of PCa, while the upper confidence interval close to 1.00. Therefore the result of this part needs to be explained with caution. At last, limited prospective sequential data was available at the moment, lowering the strength of evidence in this meta-analysis.

Conclusion

In summary, our work demonstrated that statins use could not lower PCa recurrence risk among all patients underwent RP. Although the improved outcomes might be seen among statins users who underwent RT, more future studies excluded men who received ADT pre- or post-radiation therapy should be done. In addition, statins use decreased the prostate cancer-specific mortality risk. A plausible trend towards increasing the BCR-free survival rate among statins users was also observed.

Additional Information

How to cite this article: Tan, P. et al. The effect of statins on prostate cancer recurrence and mortality after definitive therapy: a systematic review and meta-analysis. Sci. Rep. 6, 29106; doi: 10.1038/srep29106 (2016).